



Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting

La Chaux-de-Fonds, Switzerland, Mar. 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical models of Gastrointestinal (GI) cancers.

Highlights from the poster include:

- *Treatment of GI cancer cell lines with single-agent RP4010 decreased cell growth*
- *RP4010 synergized with gemcitabine and nab-paclitaxel in Pancreatic Ductal Adenocarcinoma (PDAC)*
- *RP4010 synergized with nab-paclitaxel in Gastric Cancer (GC)*
- *RP4010 significantly enhanced the activity of everolimus in Pancreatic Neuroendocrine Tumors (PNETs)*

About RP4010:

RP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers. Blockade of store-operated calcium entry (SOCE) through CRAC channel inhibition could suppress tumor growth via a number of downstream events including inhibition of NFAT dephosphorylation as well as calcium-dependent activation of Akt/NF- κ B and ERK 1/2 pathways. A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010, a CRAC channel inhibitor in patients with relapsed or refractory Lymphomas is currently ongoing in USA and Australia (ClinicalTrials.gov Identifier: NCT03119467).

Details of the poster presentation:

-- Poster Title: Efficacy of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor, in preclinical models of gastrointestinal cancers

- Session Category: Experimental and Molecular Therapeutics
- Session Title: Novel Antitumor Agents 1
- Session Date & Time: Tuesday, April 2, 2019; 8:00 AM – 12:00 PM
- Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 14
- Poster Board Number: 3
- Permanent Abstract No.: 3069

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, www.rhizen.com.

Contact:

Kumar V. Penmetsa, Ph.D.
Executive Vice President, Corporate Development
Rhizen Pharmaceuticals S.A.
Telephone: +1-267-207-5707
Email: kvp@rhizen.com